Skip to main content

Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study

Investigational New Drugs volume 10, pages 165–170 (1992)Cite this article

Summary

Difluorodeoxycytidine (dFdC) demonstrated broad spectrum activity in preclinical models. A phase 1 study utilizing twice weekly injections was conducted in 50 eligible and evaluable patients. Twenty-nine patients received drug by 30 minute infusion at doses of 5–90 mg/m2 and 22, by 5 minute bolus at 30–150 mg/m2. The primary dose limiting toxicities were marrow suppression and flu-like symptomatology. Thrombocytopenia was dose limiting at 75 mg/m2 on the infusion schedule and 150 mg/m2 on the 5 minute schedule. Flu-like symptoms with fever, rigors and malaise occurred the day of injection in many patients. One patient with renal cell carcinoma attained a partial response. Evaluation of the drug's efficacy and schedule dependency continue.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Tanis B, Clavel M, Guastalla J,et al.: Phase I study of gemcitabine (diFluorodeoxycytidine; dFdC; (LY188011) administered in a two-weekly schedule. Proc AACR 31: 1230, 1990

    Google Scholar 

  2. Brown T, O'Rourke T, Burris H,et al.: A phase I trial of gemcitabine (LY188011) administered IV every two weeks. Proc ASCO 10: 328, 1991

    Google Scholar 

  3. O'Rourke T, Brown T, Havlin K,et al.: Phase I trial and immunologie assessment of difluorodeoxycytidine. Proc ASCO 8: 320, 1989

    Google Scholar 

  4. Casper CS, Green MR, Brown TD,et al.: Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with pancreatic cancer. Proc ASCO 10: 440, 1991

    Google Scholar 

  5. Anderson H, Lund B, Hansen HH,et al.: Phase II study of gemcitabine in non small cell lung cancer (NSCLC). Proc ASCO 10: 848, 1991

    Google Scholar 

  6. Abbruzzese JL, Grunewald R, Weeks EA,et al.: A phase I clinical plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491, 1991

    PubMed  Google Scholar 

  7. Grindey GB, Boder GB, Hertel LW,et al.: Antitumor activity of 2′2′ difluorodeoxycytidine (LY188011). Proc AACR 27: 1175, 1986

    Google Scholar 

  8. Burke T, Grindey GB, Hertel LH, Rinzel S, Worzalla J, Boder GB: Cellular distribution of gemcitabine (LY188011). Proc AACR 31: 2040, 1990

    Google Scholar 

  9. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′2′ difluorodeoxycytidine and 1β D-Arabinofurosylcytosine. Cancer Res 48: 4024–4031, 1988

    PubMed  Google Scholar 

  10. Hertel LW, Boder GB, Kroin JS,et al.: Evaluation of the antitumor activity of Gemcitabine, (difluor-2′-deoxycytidine). Cancer Research 50: 4417–22, 1990

    PubMed  Google Scholar 

  11. Data on file. Eli Lilly Company, Indianapolis, Indiana

  12. Corbett T. Unpublished results

  13. Grindey G. Unpublished data

  14. Miller AB, Hoogstraten B, Staquet B,et al.: Reporting results of cancer treatment. Cancer 47: 207–2224, 1981

    PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine, 48202-0188, Detroit, Michigan, USA

    Elizabeth A. Poplin, Thomas Corbett, Lawrence Flaherty, Bruce G. Redman, Manuel Valdivieso & Laurence Baker

  2. Lilly Corporation, Building 31/3, 46206, Indianapoli, Indiana, USA

    Peter Tarasoff

Authors
  1. Elizabeth A. Poplin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Corbett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Tarasoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bruce G. Redman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manuel Valdivieso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laurence Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Poplin, E.A., Corbett, T., Flaherty, L. et al. Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study. Invest New Drugs 10, 165–170 (1992). https://doi.org/10.1007/BF00877241

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877241

Key words

  • gemcitabine
  • difluorodeoxycytidine
  • phase I study